April 17, 2017 10:16 AM EDT

CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief

Shehla Shakoor

Managing Director

→ CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

CRISPR Ther­a­peu­tics, Case­bia ink AAV deal with Stride­Bio; Puma gets an Ad­Comm date; Mer­ri­mack names new R&D chief

Managing Director

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief